MedTrace Logo

Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

NCT01065935 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2018-02-05

No results posted yet for this study

Summary

To evaluate the efficacy and safety of ALN-RSV01 plus standard of care in RSV infected lung transplant patients

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

DRUG

ALN-RSV01

Administered by nebulization once daily for 5 days

DRUG

Normal Saline

Administered by nebulization once daily for 5 days

Sponsors & Collaborators

Principal Investigators

  • Martin Zamora, MD · University of Colorado, Denver

  • Alan Glanville, MB BS MD Syd, FRACP · St. Vincents Hospital NSW W Australia

  • Jens T Gottlieb, MD · Hannover Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2012-04-30
Completion
2012-05-31

Countries

  • United States
  • Australia
  • Austria
  • Canada
  • France
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01065935 on ClinicalTrials.gov